Process for preparing polymorph form II of tanaproget

Details Process for preparing polymorph form II of tanaproget Process for preparing polymorph form II of tanaproget

2011-06-28

2011-06-28

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Chalcogen in the nitrogen containing substituent

Reexamination Certificate

active

07968709

ABSTRACT:
Tanaproget polymorph Form II, processes for preparing tanaproget polymorph Form II, pharmaceutical compositions including tanaproget polymorph Form II, micronized tanaproget polymorph Form II, and processes for converting Form II to tanaproget Form I are provided. Also provided are methods of contraception, hormone replacement therapy, stimulation of food intake and treating or preventing uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, or carcinomas and adenocarcinomas comprising administering polymorph Form II to a mammalian subject.

REFERENCES:
patent: 6436929 (2002-08-01), Zhang
patent: 7081457 (2006-07-01), Zhang
patent: 7192956 (2007-03-01), Fensome
patent: 7268149 (2007-09-01), Fensome
patent: 7569564 (2009-08-01), Zhang
patent: 7569679 (2009-08-01), Shen
patent: 2006/0246128 (2006-11-01), Nagi
patent: 2006/0246135 (2006-11-01), Nagi
patent: 2006/0247234 (2006-11-01), Nagi
patent: 2006/0247236 (2006-11-01), Chatlapalli
patent: 2006/0280800 (2006-12-01), Nagi
patent: WO-00/66570 (2000-11-01), None
patent: WO-2005/104711 (2005-11-01), None
patent: WO-2005/105817 (2005-11-01), None
Fensome, “Synthesis and Structure-Activity Relationship of Novel 6-Ary1-1,4-dihydrobenzo[d][1.3]oxazine-2-thiones as Progesterone Receptor Modulators Leading to the Potent and Selective Nonsteroidal Progesterone Receptor Agonists Tanaproget” Journal of Medicinal Chemistry, vol. 48, pp. 5092-5092 (Jul. 12, 2005).
Zhang, “Novel 6-Ary1-1,4-dihydrobenzo[d][1,3]oxazine-2-thiones as Potent, Selective, and Orally Active Nonsteroidal Progesterone Receptor Agonists”, Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 1313-1316 (Apr. 7, 2003).
Winneker, “Nonsteroidal Progesterone Receptor Modulators: Structure Activity Relationships”, Seminars in Reproductive Medicine, 23(1):46 (Feb. 2005).
Borka, “Crystal Polymorphism of Pharmaceuticals”, Acta Pharmaceutica Jugoslavia, vol. 40, pp. 71-94, (1990).
Bapst, “Clinical Pharmacokinetics of Tanaproget, A Non-Steroidal Progesterone Receptor (PR) Agonist, in Healthy Cycling Women During 28 Days of Administration”, American Society for Clinical Pharmacology and Therapeutics, Abstract PI-138, (Feb. 2005), p. 44.
Crabtree, “Development of a Mouse Model of Mammary Gland Versus Uterus Tissue Selectivity Using Estrogen- and Progesterone-Regulated Gene Markers”, Journal of Steroid Biochemistry & Molecular Biology, vol. 101, (Sep. 2006; e-published Aug, 22, 2006), pp. 11-21.
Bapst, “Pharmacokinetics and Safety of Tanaproget, a Nonsteroidal Progesterone Receptor Agonist, in Healthy Woman”, Contraception, vol. 74 (Nov. 2006; e-published Sep. 15, 2006), pp. 414-418.
Bruner-Tran, “Down-Regulation of Endometrial Matrix Metalloproteinase-3 and—7 Expression in Vitro and Therapeutic Regression of Experimental Endometriosis in Vivo by a Novel Nonsteroidal Progesterone Receptor Agonist, Tanaproget”, Journal of Clinical Endocrinology & Metabolism, vol. 91, No. 4 (Apr. 2006; e-published Jan. 17, 2006), pp. 1554-1560.
Rasenack, “Microcrystals for Dissolution Rate Enhancement of Poorly Water-Soluble Drugs”, International Journal of Pharmaceutics, vol. 254, pp. 137-145 (Mar. 26, 2003).
International Search Report issued in International Patent Application No. PCT/US06/015852 (Oct. 2, 2006).
English translation of an Office Action issued in Chinese Patent Application No. 200680014221.8 (dated Dec. 4, 2009).
Office Action issued in U.S. Appl. No. 11/412,015 (Nov. 12, 2008).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/412,015 (Nov. 12, 2008).
Office Action issued in U.S. Appl. No. 11/412,015 (Apr. 2, 2009).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/412,015 (Apr. 2, 2009).
Office Action issued in U.S. Appl. No. 11/412,015 (Nov. 27, 2009).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/412,015 (Nov. 27, 2009).
Office Action issued in U.S. Appl. No. 11/412,016 (Nov. 12, 2008).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/412,016 (Nov. 12, 2008).
Office Action issued in U.S. Appl. No. 11/412,016 (Aug. 19, 2009).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/412,016 (Aug. 19, 2009).
Office Action issued in U.S. Appl. No. 11/412,016 (Apr. 29, 2010).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/412,016 (Apr. 29, 2010).
Office Action issued in U.S. Appl. No. 11/411,523 (Oct. 1, 2008).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/411,523 (Oct. 1, 2008).
Office Action issued in U.S. Appl. No. 11/411,523 (Mar. 4, 2009).
Applicants' Response to the Office Action issued in U.S. Appl. No. 11/411,523 (Mar. 4, 2009).
Correspondence from the Mexican associate regarding an Office Action issued on Jul. 12, 2010 in Mexican Patent Application No. MX/a/2007/013469.

Affiliated with

Also associated with

Rating

Process for preparing polymorph form II of tanaproget does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Process for preparing polymorph form II of tanaproget, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for preparing polymorph form II of tanaproget will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2732552